The robust clinical success in the treatment of ALL has attracted a lot of attention on CAR T cell approaches, with one anti-CD19 based therapy expected to soon be granted FDA approval for the treatment of pediatric ALL (102). Here, CD19 is linked to acute lymphoblastic leukemia.